KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Total Current Liabilities: 2011-2025

Historic Total Current Liabilities for Supernus Pharmaceuticals (SUPN) over the last 14 years, with Sep 2025 value amounting to $330.6 million.

  • Supernus Pharmaceuticals' Total Current Liabilities rose 13.42% to $330.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $330.6 million, marking a year-over-year increase of 13.42%. This contributed to the annual value of $292.4 million for FY2024, which is 0.76% up from last year.
  • Latest data reveals that Supernus Pharmaceuticals reported Total Current Liabilities of $330.6 million as of Q3 2025, which was up 15.46% from $286.4 million recorded in Q2 2025.
  • Supernus Pharmaceuticals' 5-year Total Current Liabilities high stood at $735.5 million for Q2 2022, and its period low was $234.7 million during Q3 2021.
  • Its 3-year average for Total Current Liabilities is $333.4 million, with a median of $291.5 million in 2024.
  • As far as peak fluctuations go, Supernus Pharmaceuticals' Total Current Liabilities soared by 209.31% in 2022, and later plummeted by 65.66% in 2023.
  • Quarterly analysis of 5 years shows Supernus Pharmaceuticals' Total Current Liabilities stood at $315.4 million in 2021, then spiked by 118.14% to $688.0 million in 2022, then tumbled by 57.82% to $290.2 million in 2023, then increased by 0.76% to $292.4 million in 2024, then climbed by 13.42% to $330.6 million in 2025.
  • Its Total Current Liabilities stands at $330.6 million for Q3 2025, versus $286.4 million for Q2 2025 and $281.8 million for Q1 2025.